|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this investigator-initiated, randomised, open-label, assessor-blinded, multicentre trial (TROPICAL-ACS) done at 33 sites in Europe, patients were enrolled if they had biomarker-positive acute coronary syndrome with successful PCI and a planned duration of dual antiplatelet treatment of 12 months.
|
28855078 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, it is not easy to make a complete changeover to NOACs in real-world clinical practice because NOACs still have challenges in specific patient populations (eg, Asian patients, NVAF patients presenting with acute coronary syndrome [ACS], dialysis patients with NVAF, patients with cancer-associated VTE, etc.).
|
31632045 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analyses were repeated stratified by whether or not the procedure had been performed in the setting of an acute coronary syndrome ( ACS ).
|
30642222 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Extracted data included baseline cardiac status, dosimetric parameters to the whole heart (WH) and cardiac substructures, and the development of post-CRT symptomatic cardiac events (acute coronary syndrome [ACS], arrhythmia, pericardial effusion, pericarditis, and congestive heart failure [CHF]).
|
29883836 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The difference in clinical presentations (acute coronary syndrome [ACS] and stable coronary artery disease [SCAD]) and related angiographic morphologies of sirolimus-eluting stent (SES) failure requiring target lesion revascularization (TLR) during early-term (<1year), late-term (1-5years), and very late-term periods (>5years) remains unknown.
|
28545849 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risk stratification after percutaneous coronary intervention (PCI) is mainly based on demographics and clinical presentation (stable coronary artery disease [CAD] vs. acute coronary syndromes [ACS]).
|
30041804 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 1,121,359 cases (103,887 EVT cases for critical limb ischemia [CLI] or intermittent claudication and 1,017,472 PCI cases for acute coronary syndrome [ACS] or stable angina) were analyzed.
|
31730004 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We enrolled 111 patients (82 with stable CAD and 29 with acute coronary syndromes [ACS]) who underwent coronary angiography.
|
28511772 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
(Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome [ACS] [VAMPIRE3]; NCT01460966).
|
30077678 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The TRANSLATE-ACS study (Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome) assessed employment status at baseline and 1 year among 9319 patients with MI (mean age, 60.8 years; SD, 11.3; 27.3% women) enrolled at 233 US hospitals.
|
29895612 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Each offers a relative efficacy benefit (dual antiplatelet therapy [DAPT] is more effective than OAC alone in reducing cardiovascular death, myocardial infarction, stent thrombosis, and ischemic coronary events in a population with acute coronary syndromes [ACS]), but with a relative compromise (DAPT is significantly inferior to OAC for the prevention of stroke/systemic embolism in an AF population at increased risk of stroke).
|
30404748 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Background Obstructive sleep apnea ( OSA ) is a novel risk factor for acute coronary syndrome ( ACS ).
|
30371252 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background The prognostic significance of obstructive sleep apnea ( OSA ) in patients with acute coronary syndrome ( ACS ) in the contemporary era is unclear.
|
30636505 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conflicting evidence exists about the impact of marital status on the outcomes of patients with acute coronary syndrome ( ACS ).
|
31266391 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dialysis patients had more comorbidities than nondialysis patients and higher rates of complications including in-hospital mortality (3.3% vs. 1.5%, respectively, in the acute coronary syndrome [ACS] cohort, 0.2% vs. 0.1% in the non-ACS cohort) and bleeding complications requiring blood transfusion (1.1% vs. 0.4% in ACS, 0.5% vs. 0.2% in non-ACS).
|
30467967 |
2019 |
|
Stable angina
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Prospective cohort study of 75 stable patients with CAD and 3 differing clinical profiles (stable angina [SA]; remote myocardial infarction [MI]; repetitive acute coronary syndrome [ACS]) and 25 controls without angiographic CAD, each with 15 hs-cTnT measurements over 1 year.
|
31679620 |
2019 |
|
Stable angina
|
0.090 |
Biomarker
|
disease |
BEFREE |
Patients were grouped according to the form of CAD (ACS vs. stable angina) and the number of diseased vessels.
|
22773402 |
2012 |
|
Stable angina
|
0.090 |
Biomarker
|
disease |
BEFREE |
We evaluated 145 native coronary lesions (89 lesions with stable angina pectoris [SAP] and 56 with acute coronary syndrome [ACS]).
|
28233628 |
2017 |
|
Stable angina
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
These 4215 procedures were evaluated for three different categories: diagnostic CA (Group I), PCI in patients with stable angina (Group II), and PCI in patients with ACS (Group III).
|
31264653 |
2019 |
|
Stable angina
|
0.090 |
Biomarker
|
disease |
BEFREE |
Genotyping was performed in 1,598 CAD subjects (ACS or stable angina) and 332 controls.
|
17044867 |
2006 |
|
Stable angina
|
0.090 |
Biomarker
|
disease |
BEFREE |
The patients were divided in 4 groups: patients without coronary artery disease (control group), patients with stable angina pectoris (SAP group), patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS group), and patients with ST-segment elevation acute myocardial infarction group (STEMI group).
|
30898992 |
2019 |
|
Stable angina
|
0.090 |
Biomarker
|
disease |
BEFREE |
Gene expression profiles were determined in RNA pools from resting platelets of patients with stable angina (SA, n = 14) or NSTE-ACS (n = 15) using a glass microarray platform.
|
21420725 |
2011 |
|
Stable angina
|
0.090 |
Biomarker
|
disease |
BEFREE |
We measured baseline sEPCR levels in 1673 individuals with CAD (521 with acute coronary syndrome [ACS] and 1152 with stable angina pectoris [SAP]) from the AtheroGene cohort.
|
23136988 |
2012 |
|
Stable angina
|
0.090 |
Biomarker
|
disease |
BEFREE |
Data in SA and ACS groups were replicated in an independent population of 482 stable angina patients (rSA) and of 675 ACS patients, respectively.
|
22575314 |
2012 |
|
Coronary Artery Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
External validation in stable CAD (c = 0.65) and ACS (c = 0.68) demonstrated comparable performance.
|
31623766 |
2019 |